BioNTech SE develops immunotherapies and mRNA vaccines aimed at improving global health. The company focuses on oncology, offering a portfolio that includes mRNA cancer immunotherapies, immunomodulators, and targeted therapies. BioNTech also works on mRNA vaccine programs for infectious diseases, leveraging the technology used in its COVID-19 vaccine. Its research and development efforts are directed towards harnessing the immune system to combat cancer, infectious diseases, and other serious conditions.
- Website
- biontech.de
- Issuer profile
- All listings